Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME, Chung KY, Debruyne PR, Fox JR, Gambardella V, Gil-Martin M, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O'Malley DM, Olawaiye AB, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann PR. Okines AFC, et al. Among authors: takahashi s. Nat Med. 2025 Jan 17. doi: 10.1038/s41591-024-03462-0. Online ahead of print. Nat Med. 2025. PMID: 39825152
The incidence and risk factor for febrile urinary tract infection after robot-assisted laparoscopic radical cystectomy in bladder cancer patients.
Hiyama Y, Shindo T, Takahashi A, Fukuta F, Maehana T, Tachikawa K, Hashimoto K, Kobayashi K, Tanaka T, Takahashi S, Masumori N; Sapporo Medical University Urologic Oncology Consortium. Hiyama Y, et al. Among authors: takahashi s. J Infect Chemother. 2025 Jan 15:102624. doi: 10.1016/j.jiac.2025.102624. Online ahead of print. J Infect Chemother. 2025. PMID: 39824249
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Maćkowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS. Oaknin A, et al. Among authors: takahashi s. Eur J Cancer. 2025 Jan 10;216:115146. doi: 10.1016/j.ejca.2024.115146. Online ahead of print. Eur J Cancer. 2025. PMID: 39798514
11,462 results
You have reached the last available page of results. Please see the User Guide for more information.